Lipocine (NASDAQ:LPCN) Share Price Crosses Above Fifty Day Moving Average – Here’s Why

Shares of Lipocine Inc. (NASDAQ:LPCN) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.21 and traded as high as $2.27. Lipocine shares last traded at $2.22, with a volume of 27,319 shares.

Analyst Ratings Changes

LPCN has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings lowered Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $15.00.

Lipocine Stock Performance

The company has a market capitalization of $17.81 million, a price-to-earnings ratio of -1.21 and a beta of 0.47. The firm has a 50-day simple moving average of $2.20 and a two-hundred day simple moving average of $3.27.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. As a group, equities analysts forecast that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Lipocine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LPCN. Eversept Partners LP purchased a new stake in shares of Lipocine during the first quarter worth $2,357,000. AIGH Capital Management LLC purchased a new position in Lipocine in the first quarter valued at $1,598,000. Stempoint Capital LP purchased a new position in Lipocine in the first quarter valued at $1,282,000. Seven Fleet Capital Management LP acquired a new position in Lipocine during the 1st quarter worth $998,000. Finally, Persistent Asset Partners Ltd acquired a new position in Lipocine during the 4th quarter worth $567,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.